WM
53
2
THC
52
9
HCA
37
7
COF
48
3
HIG
48
5
NWS
69
5
TRV
34
4
LEG
16
2
JBHT
46
4
MTCH
62
22
CME
59
3
CI
35
2
FITB
36
3
ROK
46
3
PX
56
3
MRK
25
2
HBAN
47
7
URBN
67
3
UAL
73
3
ED
39
8
WM
53
2
THC
52
9
HCA
37
7
COF
48
3
HIG
48
5
NWS
69
5
TRV
34
4
LEG
16
2
JBHT
46
4
MTCH
62
22
CME
59
3
CI
35
2
FITB
36
3
ROK
46
3
PX
56
3
MRK
25
2
HBAN
47
7
URBN
67
3
UAL
73
3
ED
39
8
Financhill
Back

Relay Therapeutics 10K Form

Sell
15

RLAY
Relay Therapeutics

Last Price:
$4.17
Seasonality Move:
-14.64%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RLAY News And Ratings

See the #1 stock for the next 7 days that we like better than RLAY

RLAY Financial Statistics

Sales & Book Value

Annual Sales: $25.5M
Cash Flow: $-75.3M
Price / Cash Flow: 0
Annual Sales: $5.03
Price / Book: 0.83

Profitability

EPS (TTM): -2.61000
Net Income (TTM): $-345.2M
Gross Margin: --
Return on Equity: -41.45%
Return on Assets: -35.84%

Relay Therapeutics Earnings Forecast

Key Relay Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,291.86% of Revenue.
  • The Net Earning history of RLAY is -1,338.66% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Relay Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RLAY
CUSIP: 75943R
Website: relaytx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 20.73
Quick Ratio: 20.18

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RLAY Technical Analysis vs Fundamental Analysis

Sell
15
Relay Therapeutics (RLAY) is a Sell

Is Relay Therapeutics a Buy or a Sell?